As Metabolic Solutions moves forward in the development of our lead therapeutic candidates, we have begun negotiations with key potential business allies:

• Global biopharmaceutical companies – clinical trial services
• Asian-based pharmaceutical companies – API optimization, manufacturing, and global development program
• Academic collaborations to further define the unique mechanisms of action for PPARγ-sparing insulin sensitizers

We will post further information about these significant alliances as they develop.